Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 19Lymphoid 12CNS 12Myeloid 9Head & Neck 9Gastrointestinal 7Thoracic 5Sarcoma 5Other solid neoplasm 5Gynecologic 5Dermatologic 4Genitourinary 3Breast 3Tumor-Agnostic 2Other neoplasm 1Classical hematology 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Valproic Acid × Tumor-Agnostic × Clear all
NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

National Cancer Institute, Naples

Phase 2 Recruiting
240 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00246103 2017-02-23

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
82 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡